drugset / Trial / NCT05994456
Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open phase II clinical trial to evaluate the tolerability, safety and efficacy of toriparib monotherapy in the treatment of locally advanced dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |